2. Next‐generation ALK versus crizotinib: median progression‐free survival and overall survival.
| Study | Median progression‐free survival | Median overall survival | Median follow‐up | Median overall survival | Median follow‐up | % Cross‐over | |
|
Next‐generation ALK inhibitor months (95% CI) |
Crizotinib months (95% CI) |
Next‐generation ALK inhibitor months (95% CI) |
Next‐generation ALK inhibitor months |
Crizotinib months (95% CI) |
Crizotinib | ||
| ALEX 2017 | 34.8 (17.7 to NE) | 10.9 (9.1 to 12.9) | NR (NR to NR) | 48.2 | 57.4 (34.6 to NR) | 23.3 | 0 |
| J‐ALEX 2017 | 34.1 (22.1 to NE) | 10.2 (8.3 to 12) | NE (NE to NE) | 42.4 | 43.7 (41.5 to NE) | 42.2 | 0 |
| ALTA‐1L 2019 | NR (NR to NR) | 9.8 (9.0 to 12.9) | NR (NR to NR) | 24.9 | NR (NR to NR) | 15.2 | 25.4 |
| ALESIA 2019 | NE (16.7 to NE) | 10.7 (7.4 to NE) | NR (NR to NR) | 27.8 | NR (NR to NR) | 22.8 | 0 |
| CROWN 2020 | NE (NR to NR) | 9.3 (7.6 to 11.1) | NR (NR to NR) | 18.3 | NR (NR to NR) | 14.8 | 0 |
CI: confidence interval NE: not estimable NR: not reached